A Massachusetts biotechnology company is laying off 21 employees in Durham amid a broader restructuring and pressure from federal regulators.

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Just how many employees is Sarepta Therapeutics laying off? And why did the FDA reject Ultragenyx's rare disease drug over ...

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

After the FDA request, Cambridge, Massachusetts-based Sarepta said in a statement that it will continue to ship the therapy to ambulatory people but maintain a halt it implemented June 15 for ...

In the preceding three months, 38 analysts have released ratings for Sarepta Therapeutics SRPT, presenting a wide array of perspectives from bullish to bearish. The table below provides a concise ...

FDA is investigating Sarepta's Elevidys after two deaths from liver failure in non-ambulatory DMD patients, raising safety and regulatory concerns.

Both patients were teenage boys who passed away after developing acute liver failure within two months after treatment with Sarepta’s one-time therapy.

FDA evaluating further regulatory actions after deaths Elevidys is the only gene therapy for Duchenne muscular dystrophy Sarepta suggested updating Elevidys' label June 24 (Reuters) - The U.S ...

Sarepta Therapeutics slashed its share price by 44 percent last week following price target cuts from two investment companies. In a market note, Oppenheimer significantly lowered its price target ...

Today's biotech news features an FDA probe into the deaths tied to Sarepta's Duchenne drug, rejecting KalVista's drug application, etc.

Sarepta Therapeutics' headquarters at 215 First St. in Cambridge. The FDA is conducting an investigation following the deaths of two patients treated with Sarepta’s gene therapy for Duchenne ...